Demo Data from EDBT 2026 / reviewers in the wild / expert
Martin Daumer
dblp:81/374
· DBLP profile ↗
2ranked-venue papers
0as first author
0since 2021 · last 2008
—ORCID · none
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 2
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% |
Topics — the 2 heaviest of 2, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology
clinical bioinformatics |
0.1 | 1 | 2008 | Microarray-based classification and clinical predictors: on combined classifiers and additional predictive value · Bioinform. 2008 |
Bioinformatics and computational biology › gene expression analysis › gene expression classification
microarray classification |
0.0 | 1 | 2008 | Microarray-based classification and clinical predictors: on combined classifiers and additional predictive value · Bioinform. 2008 |
Methods — techniques the papers use, named apart from their topics
random forest · 0.1pre-validation · 0.1partial least squares · 0.1cross-validation · 0.1
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2008 | Microarray-based classification and clinical predictors: on combined classifiers and additional predictive valueabstractMOTIVATION: In the context of clinical bioinformatics methods are needed for assessing the additional predictive value of microarray data compared to simple clinical parameters alone. Such methods should also provide an optimal prediction rule making use of all potentialities of both types of data: they should ideally be able to catch subtypes which are not identified by clinical parameters alone. Moreover, they should address the question of the additional predictive value of microarray data in a fair framework. RESULTS: We propose a novel but simple two-step approach based on random forests and partial least squares (PLS) dimension reduction embedding the idea of pre-validation suggested by Tibshirani and colleagues, which is based on an internal cross-validation for avoiding overfitting. Our approach is fast, flexible and can be used both for assessing the overall additional significance of the microarray data and for building optimal hybrid classification rules. Its efficiency is demonstrated through simulations and an application to breast cancer and colorectal cancer data. AVAILABILITY: Our method is implemented in the freely available R package 'MAclinical' which can be downloaded from http://www.stat.uni-muenchen.de/~socher/MAclinical Anne-Laure Boulesteix, Christine Porzelius, Martin Daumer |
Bioinform. | 3 |
| 2008 | CMA - a comprehensive Bioconductor package for supervised classification with high dimensional dataabstractBACKGROUND: For the last eight years, microarray-based classification has been a major topic in statistics, bioinformatics and biomedicine research. Traditional methods often yield unsatisfactory results or may even be inapplicable in the so-called "p >> n" setting where the number of predictors p by far exceeds the number of observations n, hence the term "ill-posed-problem". Careful model selection and evaluation satisfying accepted good-practice standards is a very complex task for statisticians without experience in this area or for scientists with limited statistical background. The multiplicity of available methods for class prediction based on high-dimensional data is an additional practical challenge for inexperienced researchers. RESULTS: In this article, we introduce a new Bioconductor package called CMA (standing for "Classification for MicroArrays") for automatically performing variable selection, parameter tuning, classifier construction, and unbiased evaluation of the constructed classifiers using a large number of usual methods. Without much time and effort, users are provided with an overview of the unbiased accuracy of most top-performing classifiers. Furthermore, the standardized evaluation framework underlying CMA can also be beneficial in statistical research for comparison purposes, for instance if a new classifier has to be compared to existing approaches. CONCLUSION: CMA is a user-friendly comprehensive package for classifier construction and evaluation implementing most usual approaches. It is freely available from the Bioconductor website at (http://bioconductor.org/packages/2.3/bioc/html/CMA.html). Martin Slawski, Martin Daumer, Anne-Laure Boulesteix |
BMC Bioinform. | 2 |